Cervical Disc Replacement for Spondylotic Myeloradiculopathy

Background

Cervical disc replacement is a newer concept and rapidly developing surgical treatment. A prospective study was conducted to determine, if accurately implanted Bryan''s cervical disc prostheses can provide relief from objective neurological symptoms and signs, stability and normal range of motion in cases of cervical disc prolapse with myeloradiculopathy.

Material and Method

Twenty patients underwent Bryan cervical disc replacement from Jan 2002 to Dec 2003. Young patients between age groups 21 to 50 years with degenerative cervical disc prolapse at C3-C7 with myeloradiculopathy were included in this study. Patients with significant facet joint arthropathy, unstable spine, trauma, tumour, osteoporosis and active infection were excluded from this study. Nurick''s grading was used for quantifying the neurological deficit. Patients were operated by anterior cervical approach using a specially designed Bryan''s cervical discectomy system. Neurological and radiological outcome was assessed post operatively and at 2,6,12 and 24 months follow up. Outcome analysis was carried out using modified Odom''s criteria. The radiographic results were assessed by taking antero posterior (AP) and lateral radiographs of cervical spine to find range of motion and device position.

Results

The patients were in the age group of 31 to 50 years. There were 14 (70%) male and 6 (30%) female in this study. Neck pain and brachialgia were the presenting symptoms in all cases, 12 (60%) had radiculopathy and 8 (40%) had myelopathy. Single level disc prolapse was present as per Magnetic Resonance Imaging (MRI) in four (20%) at C4-C5, 12 (60%) at C5-C6 and 4 (20%) at C6-C7. Bryan''s disc size 15 was used in 8 (40%) and size 17 was used in 12(60%) patients. During post-operative, 02, 06, 12, and 24 months follow up, the clinical outcome was excellent in 16 (80%) and good in 4 (20%) as per modified Odom''s criteria. There was demonstrated improvement in flexion, extension and rotation clinically and radiologically during follow up. There was no migration or displacement of device.

Conclusion

Cervical disc replacement for cervical disc prolapse with myeloradiculopathy represents an exciting new technology. Patients treated with the Bryan cervical disc prosthesis for single level cervical disc prolapse showed good to excellent improvement in neurological deficit. Clinically and radiologically maintenance of motion was found during follow up. More patients with longer follow up and post operative MRI to find out the protection to adjacent discs from abnormal stress will be required before this prosthesis is accepted as a treatment option.Key Words: Spondylotic myeloradiculopathy, Cervical disc replacement     

新型抗日本血吸虫病口服有效药物

最近一年多来,我們在寻找非銻剂抗血吸虫病药物方面,合成了一大类具有下列通式的化合物。在合成了的几百个这类型的化合物中,不少在动物試驗有显著的杀日本血吸虫效力。此类型的药物的化学通式为:     

血吸虫病化学治疗的研究 Ⅱ.α-取代-β-(5-硝基-2-呋喃)丙烯酰胺及酯类衍生物的合成

本文报导α-取代-β-(5-硝基-2-呋喃)丙烯酰胺及酯类衍生物85个的合成。这类化合物系分别以糠醛或硝基糠醛与相应的羧酸钾盐经Perkin反应缩合后,按一般方法制成酰胺及酯;或以相应的硝基呋喃丙烯酰胺经溴化;或通过氮内酯中间体经水解、醇解和氨解而制备。经动物篩选后发现有13个化合物对感染日本血吸虫小白鼠有作用,其中α—甲基—β-(5-硝基-2-呋喃)丙烯酰正丁胺(I₆,F-30058),α-甲基-β-(5-硝基-2-呋喃)丙烯酰乙醇胺(I₁₀,F-30141)及α-甲基-β-(5-硝基-2-呋喃)丙烯酰-2′-羟基丙胺(I₁₁,F-30111)三个具有较好抑制作用。     

9－（2－膦酰甲氧乙基）腺嘌呤及其位置异构体3－（2－膦酰甲氧乙基）腺嘌呤的合成和抗病毒活性研究

９－（２－膦酰甲氧乙基）腺嘌呤及其位置异构体３－（２－膦酰甲氧乙基）腺嘌呤的合成和抗病毒活性研究刘晓辉，王琳，贯宝和，孔漫，张兴权，陶佩珍，陈鸿珊（中国医学科学院、中国协和医科大学药物研究所，北京１０００５０；中国医学科学院、中国协和医科大学医药生物...     

中药鸦胆子化学成分的研究 (一)鸦胆子油

据本草纲目拾遗,鸦胆子一名苦参子,可治痔、治痢、治泻,其油治脱癌;裴鉴及周太炎二氏报告,鸦胆子系苦木科植物 Brucea javanica(L)Merr.的果实;吴其浚植物名实图考内载:一种鸦蛋子生云南与鸦胆子不同能治痔云。考我国于1751年何梦瑶氏曾用鸦胆子作治痢,1765年赵学敏氏在本草纲目拾遗上亦谓可治痢,张锡纯、李克惠二氏云可治慢性痢及久痢。近二十年来我国学者关于鸦胆子研究不论在化学、生理、药理方面以及临床试验均有报告,认为有截疟及治痢之效,但有中毒现象。作者由其仁中分出一种苦味甙,据浙江医学院陈志康氏研究谓有治肺吸血虫病之效。其油据于光元及李宝实二氏报告可治疣及乳头瘤。全慈光氏报告可治阿米巴痢、疟疾及杀虫。Power 及 Lees 报告,全果实含有油脂20%;其成分为油酸、亚麻仁油酸、软脂酸及硬脂酸,并含一种烟化物名 Pentatriacotane-C,熔点     

Whole-blood interferon-gamma release assay for diagnosis of tuberculous lymphadenitis

Tuberculosis remains a major problem for much of the world. Tuberculous lymphadenitis is the most common type of extrapulmonary tuberculosis, although a difficult invasive procedure is required for its diagnosis. We evaluated the usefulness of the whole-blood interferon-gamma release assay (IGRA) for diagnosis of tuberculous lymphadenitis. From January 2008 to October 2010, 108 patients underwent lymph node biopsy and the IGRA concurrently in Wonju Christian Hospital, Yonsei University Wonju College of Medicine. Among the patients, 27 were diagnosed with tuberculous lymphadenitis and 81 were diagnosed with non-tuberculous lymphadenitis. The diagnostic performances of the IGRA were evaluated. The median patient age was 33 years (interquartile range [IQR] 23.5 to 48 years), and 28 (25.9%) patients were male. No patient was administered immunosuppressive agents such as high-dose steroids or underwent chemotherapy within 90 days before the IGRA test. The IGRA was positive in 25 of 27 patients with tuberculous lymphadenitis and in 13 of 81 patients with non-tuberculous lymphadenopathy. Therefore, the sensitivity of IGRA was 92.6% (95% CI, 82.0 to 100), and the specificity was 80.2% (95% CI, 71.4 to 89.1). In the patients with positive IGRA results, the INF-γ concentration was significantly higher in the patients with tuberculous lymphadenitis compared to that in the patients without tuberculous lymphadenitis (15.58 [IQR 6.87 to 45.10] IU/mL versus 0.97 [IQR 0.65 to 2.41] IU/mL, p < 0.001). In conclusion, the IGRA is helpful for the diagnosis of tuberculous lymphadenitis.